Compare MAX & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAX | VALN |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.5M | 536.9M |
| IPO Year | 2020 | 2021 |
| Metric | MAX | VALN |
|---|---|---|
| Price | $10.76 | $5.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $12.70 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 552.1K | 23.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.81 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,113,600,000.00 | N/A |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $8.16 | $93.87 |
| P/E Ratio | $49.29 | ★ N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $7.09 | $5.06 |
| 52 Week High | $13.92 | $12.25 |
| Indicator | MAX | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 70.54 | 37.71 |
| Support Level | $10.54 | $5.11 |
| Resistance Level | $13.83 | $6.69 |
| Average True Range (ATR) | 0.54 | 0.18 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 94.11 | 17.17 |
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.